Ophthalmic Solution Safety Profile: Active Surveillance of a Sodium Hyaluronate/Chondroitin Sulfate Combination in Peruvian Population

References

• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510.
   PubMed Web of Science ®Google Scholar
• Phadatare S, Momin M, Nighojkar P, Askarkar S, Singh K. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges. Adv Pharm. 2015;2015:1–12.
   Google Scholar
• Hom M, Land P. Prevalence and severity of symptomatic dry eyes in hispanics. Optom Vis Sci. 2005;82(3):206–208. doi:10.1097/01.OPX.0000156310.45736.FA
   Web of Science ®Google Scholar
• Graue-Hernández E, Serna-Ojeda J, Estrada-Reyes C, Navas A, Arrieta-Camacho J, Jimenez-Corona A. Dry eye symptoms and associated risk factors among adults aged 50 or more years in Central Mexico. Salud Publica Mex. 2018;60(5, sep–oct):520. doi:10.21149/9024
   Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.
   PubMed Web of Science ®Google Scholar
• Duran L, Delgado JÁ, Rubio YC, et al. Estudio de la seguridad y eficacia del hialuronato de sodio y sulfato de condroitín versus carboximetilcelulosa en el síndrome de ojo seco. Rev Mex Oftalmol. 2008;82:86–90.
   Google Scholar
• Belalcázar-Rey S, Sánchez Huerta V, Ochoa-Tabares JC. et al. Efficacy and safety of sodium hyaluronate/chondroitin sulfate preservative-free ophthalmic solution in the treatment of dry eye: a clinical trial. Curr Eye Res. 2020:1–11. doi:10.1080/02713683.2020.1849733
   Web of Science ®Google Scholar
• Durairaj C. Ocular Pharmacokinetics BT - Pharmacologic Therapy of Ocular Disease. Whitcup SM, Azar DT, eds. Springer International Publishing; 2017:31–55.
   Google Scholar
• Beninger P. Pharmacovigilance: an overview. Clin Ther. 2018;40(12):1991–2004. doi:10.1016/j.clinthera.2018.07.012
   PubMed Web of Science ®Google Scholar
• Garotta F, Messa A. Safety profile of ceftizoxime: an Italian experience on 14,007 patients. J Chemother. 1991;3(Suppl 2):36–38.
   Google Scholar
• Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013;65(4):143–166. doi:10.4081/reumatismo.2013.143
   Google Scholar
• Li X, Li H, Deng J, et al. Active pharmacovigilance in China: recent development and future perspectives. Eur J Clin Pharmacol. 2018;74(7):863–871. doi:10.1007/s00228-018-2455-z
   PubMed Web of Science ®Google Scholar
• Mann M, Mengistu A, Gaeseb J, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in namibia: a cost–utility analysis. Drug Saf. 2016;39(9):859–872. doi:10.1007/s40264-016-0432-y
   Web of Science ®Google Scholar
• Moses C, Celi LA, Marshall J. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. Popul Health Manag. 2013;16(3):147–149. doi:10.1089/pop.2012.0100
   Web of Science ®Google Scholar
• ICH harmonized tripartite guideline. Pharmacovigilance planning; November 18, 2004. Available from: https://database.ich.org/sites/default/files/E2E_Guideline.pdf. Accessed May 11, 2021.
   Google Scholar
• Council for International Organization of Medical Sciences (CIOMS). Working Group IV Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. 1st ed. 1998.
   Google Scholar
• Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–2232.
   PubMedGoogle Scholar
• Naranjo A, Busto U, Sellers E, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Marner K, Møller PM, Dillon M, Rask-Pedersen E. Viscous carbomer eye drops in patients with dry eyes. Acta Ophthalmol Scand. 1996;74(3):249–252. doi:10.1111/j.1600-0420.1996.tb00086.x
   Google Scholar
• Wang I-J, Lin I-C, Hou Y-C, Hu F-R. A comparison of the effect of carbomer-, cellulose- and mineral oil-based artificial tear formulations. Eur J Ophthalmol. 2007;17(2):151–159. doi:10.1177/112067210701700202
   PubMed Web of Science ®Google Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2:CD009729. doi:10.1002/14651858.CD009729.pub2
   PubMed Web of Science ®Google Scholar
• Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64(10):999–1004. doi:10.1007/s00228-008-0494-6
   PubMed Web of Science ®Google Scholar
• Lievens C, Berdy G, Douglass D, et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a Multicenter, Double-Masked, Randomized 30-Day Study. Cont Lens Anterior Eye. 2019;42(4):443–449. doi:10.1016/j.clae.2018.12.003
   PubMed Web of Science ®Google Scholar
• Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3):404–437.
   PubMed Web of Science ®Google Scholar
• Brodwall J, Alme G, Gedde-Dahl S, et al. A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmol Scand. 1997;75(4):457–461. doi:10.1111/j.1600-0420.1997.tb00413.x
   PubMedGoogle Scholar
• Simmons PA, Liu H, Carlisle-Wilcox C, Vehige JG. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial. Clin Ophthalmol. 2015;9:665–675. doi:10.2147/OPTH.S78184
   PubMed Web of Science ®Google Scholar
• Nepp J, Schauersberger J, Schild G, et al. The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome. Biomaterials. 2001;22(24):3305–3310. doi:10.1016/S0142-9612(01)00167-3
   Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295–300.
   PubMedGoogle Scholar
• Sodium hyaluronate. Micromedex; 2020. Available from: https://www.micromedexsolutions.com/. Accessed September 25, 2020.
   Google Scholar
• Mochizuki H, Yamada M, Hato S, Nishida T. Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid. Br J Ophthalmol. 2008;92(1):108–111. doi:10.1136/bjo.2007.121533
   Web of Science ®Google Scholar
• Hughes WF. Drug-induced ocular side effects and drug interactions. Arch Ophthalmol. 1983;101(3):497.
   Google Scholar